Company

FDA Approves Bayer's Sunharbo (Asundexian) – World's First FXIa Inhibitor for Secondary Stroke Prevention
BayerETR: BAYN

FDA Approves Bayer’s Sunharbo (Asundexian) – World’s First FXIa Inhibitor for Secondary Stroke Prevention

Bayer AG (ETR: BAYN) announced that the U.S. Food and Drug Administration (FDA) has granted marketing authorization for asundexian 50 mg tablets, under the brand name Sunharbo — the first…

Charles River to Acquire Frontage's Bioanalysis and DMPK Operations for ~$470 Million – Expanding Early-Phase Laboratory Footprint in Exton, Pennsylvania

Charles River to Acquire Frontage’s Bioanalysis and DMPK Operations for ~$470 Million – Expanding Early-Phase Laboratory Footprint in Exton, Pennsylvania

Ribo Life Science Files EU Phase I CTA for SR122 – Dual‑Targeting ApoC3/PCSK9 siRNA Advancing Into Europe for Dyslipidemia

Ribo Life Science Files EU Phase I CTA for SR122 – Dual‑Targeting ApoC3/PCSK9 siRNA Advancing Into Europe for Dyslipidemia

Empowering Chinese Pharma’s Global Expansion

Leverage premier media reach to connect your pipeline with global partners. Contact us to drive your international growth today.
Contact US
Ouro Medicines Launches with $120M Series A Financing for CM336 Development
FinanceGSK

Ouro Medicines Launches with $120M Series A Financing for CM336 Development

Menarini Group Expands Oncology Pipeline with Insilico Medicine License
CancerMenarini

Menarini Group Expands Oncology Pipeline with Insilico Medicine License

Zai Lab Secures Rights to Vertex's Povetacicept in Key Asian Markets
HKG: 9688NASDAQ: ZLAB

Zai Lab Secures Rights to Vertex’s Povetacicept in Key Asian Markets

Eli Lilly in Advanced Talks to Acquire Scorpion Therapeutics for $2.5 Billion
Eli LillyNYSE: LLY

Eli Lilly in Advanced Talks to Acquire Scorpion Therapeutics for $2.5 Billion

Show More